It might not have started with your ovaries
Inositol for PCOS:
The Studies
PCOS is a metabolic condition. Around 80% of women with PCOS have insulin resistance. When cells stop responding to insulin, the body makes more of it — and high insulin pushes the ovaries toward androgen production and disrupts ovulation. That's why every study below starts with insulin. Here they are, laid out straight.
Study 1 — 70% ovulated vs 21%
Study Background
The gold standard of research: 42 women with PCOS were randomly split into two groups. One took myo-inositol, the other a placebo — and nobody, not even the researchers, knew who had which until the end. They tracked ovulation, insulin, testosterone, blood fats, and blood pressure (Costantino et al., 2009).†
Study Attributes
Placebo-Controlled
One group gets the real thing. The other gets a look-alike dummy — a placebo, here plain folic acid. Comparing the two shows what the compound actually does, beyond the effect of believing it works.
Double-Blind
Neither the women nor the researchers knew who was taking what until the study ended. That keeps hope and bias from skewing the results.
Randomized
Who got the real thing was decided by chance, like a coin flip. That keeps the two groups fair to compare.
Study 1 — The Results
MYO-INOSITOL
70%
of the women taking myo-inositol ovulated during the study (16 of 23) — versus 21% of the placebo group (4 of 19)*†
improvement in whole-body insulin sensitivity (index 2.80 → 5.05)*†
average reduction in total testosterone (99.5 → 34.8 ng/dL)*†
average drop in triglycerides — the main fat circulating in your blood (195 → 95 mg/dL)*†
Insulin Sensitivity
Insulin's job is to move sugar out of your blood and into your cells for energy. Insulin sensitivity is how well your cells listen to it — the better they listen, the less insulin your body needs and the steadier your blood sugar. In this study it was measured with a standard index, which rose from 2.80 to 5.05.
Triglycerides
Triglycerides are the main type of fat in your blood. A standard blood test measures them as one marker of metabolic health.
†Study 1: Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105–110. PubMed PMID: 19499845. This was an independent study of myo-inositol, not of Bodology.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Study 2 — Insulin down, hormones follow
Study Background
46 young women with PCOS, randomly split: half took the two inositols in the same 40:1 ratio as Bodology, half took a placebo, for six months. 40:1 isn't a marketing number — it's the balance your body naturally keeps the two inositols in (Benelli et al., 2016).‡
Study Attributes
The 40:1 Ratio
Your blood naturally holds about 40 parts myo-inositol to 1 part D-chiro-inositol. This study tested that exact balance — the same one in every scoop of Bodology.
Placebo-Controlled
One group gets the real thing. The other gets a look-alike dummy — a placebo, here plain folic acid. Comparing the two shows what the compound actually does, beyond the effect of believing it works.
Randomized
Who got the real thing was decided by chance, like a coin flip. That keeps the two groups fair to compare.
Fasting Insulin, −47%
Fasting insulin — the insulin in your blood after an overnight fast — roughly halved over the six months (20.19 → 10.74 μU/mL). The placebo group didn't change.*
HOMA Index, −42%
HOMA is a standard score doctors use to estimate insulin resistance from a simple blood test. Lower is better. It fell 42% on average (3.38 → 1.97) — and didn't budge on placebo.*
‡Study 2: Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol. 2016;2016:3204083. DOI: 10.1155/2016/3204083. Group averages; individual results vary. This was an independent study; the daily amounts studied differ from Bodology's serving.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Study 3 — The 40:1 ratio wins
Study Background
This one asked a different question: not "does inositol work?" but "which mix works best?" 56 women with PCOS were split across seven different myo-to-D-chiro blends for three months — same amount, same length, only the ratio changed (Nordio et al., 2019).§
Study Attributes
Seven Ratios, Head-to-Head
Groups got everything from pure D-chiro-inositol up to an 80:1 blend. Same total amount (2 g twice a day), same three months — so any difference in results comes down to the ratio.
Randomized
Who got which blend was decided by chance, like a coin flip. That keeps the groups fair to compare.
The 40:1 Ratio
40:1 is the balance your body naturally keeps the two inositols in — and the ratio in Bodology. In this trial it beat every other mix tested. The balance is what mattered, not more of one or the other.
Study 3 — The Results
40:1 VS EVERY OTHER RATIO
5 / 8
women on the 40:1 ratio had their period come back within 3 months — the strongest result of all seven blends tested*§
of the seven blends tested, came out on top for every hormone the researchers measured*§
how quickly progesterone — the hormone that confirms ovulation happened — started rising in the 40:1 group*§
Progesterone — the Ovulation Marker
Progesterone only rises after an egg has been released — so a blood test for it is how researchers prove ovulation actually happened, no guesswork. In the 40:1 group it was rising significantly by the end of month one.
SHBG
SHBG is a protein that binds spare hormones — including testosterone — so they can't act on the body. More SHBG means less active testosterone in circulation. In this trial, SHBG and estradiol both rose most with the 40:1 blend.
The bigger picture — ten trials, combined
Beyond single trials
Zoom out. Researchers pooled ten separate trials — 601 women in total — to ask whether the results hold up across all of them. They do: women taking inositol were more than twice as likely to ovulate, and their periods came far more regularly, than women on placebo (Pundir et al., 2018).¶*
The Numbers
Why the Journal Matters
BJOG is one of the world's leading obstetrics and gynaecology journals. Peer review at this level is a meaningful quality bar — much of the supplement literature never clears it.
Ten trials — The Results
TEN TRIALS, POOLED
2.3×
the likelihood of ovulating on inositol versus placebo, pooled across all ten trials*¶
more frequent periods on inositol than on placebo (95% CI 2.8–16.6)*¶
trials pointed the same direction on cycle frequency — rare agreement in supplement research*¶
What a Meta-Analysis Is
A meta-analysis pools many separate trials into one answer, so no single study's quirks can skew the picture. It's the strongest kind of evidence for an overall effect.
Reading the Numbers
Across all ten trials combined, women taking inositol were 2.3 times as likely to ovulate as women taking placebo (95% CI 1.1–4.7). The cycle result means periods came 6.8 times more frequently than on placebo.
§Study 3: Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512–5521. DOI: 10.26355/eurrev_201906_18223. Menses figures from Table II; progesterone and hormone findings per the published figures. Small groups (8 per ratio); this was an independent study, not of Bodology.
¶Pundir J, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299–308. DOI: 10.1111/1471-0528.14754.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
